Analysts Expect Agios Pharmaceuticals Inc (AGIO) Will Post Earnings of -$1.60 Per Share

Wall Street brokerages expect that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will announce earnings per share (EPS) of ($1.60) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Agios Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.65) and the highest is ($1.54). Agios Pharmaceuticals reported earnings of ($1.56) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 2.6%. The firm is scheduled to announce its next earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.15) per share for the current fiscal year, with EPS estimates ranging from ($6.51) to ($5.60). For the next year, analysts expect that the company will report earnings of ($4.42) per share, with EPS estimates ranging from ($6.00) to ($0.01). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.16). The company had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $12.65 million. Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. Agios Pharmaceuticals’s quarterly revenue was down 56.7% compared to the same quarter last year. During the same period last year, the firm earned ($1.34) earnings per share.

AGIO has been the topic of a number of research analyst reports. BidaskClub lowered shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 16th. Cann reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 17th. Zacks Investment Research lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 15th. Finally, Royal Bank of Canada upped their price target on shares of Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a report on Thursday, January 18th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Agios Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $85.50.

In related news, insider Christopher Bowden sold 2,000 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $77.65, for a total transaction of $155,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Carman Alenson sold 2,150 shares of the company’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $75.00, for a total transaction of $161,250.00. Following the transaction, the insider now owns 2,150 shares of the company’s stock, valued at approximately $161,250. The disclosure for this sale can be found here. Over the last three months, insiders have sold 185,114 shares of company stock worth $14,021,325. Corporate insiders own 5.43% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. Alkeon Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth about $30,489,000. UBS Asset Management Americas Inc. raised its position in shares of Agios Pharmaceuticals by 965.5% during the 4th quarter. UBS Asset Management Americas Inc. now owns 345,284 shares of the biopharmaceutical company’s stock worth $19,740,000 after purchasing an additional 312,878 shares during the last quarter. First Trust Advisors LP raised its position in shares of Agios Pharmaceuticals by 26.3% during the 4th quarter. First Trust Advisors LP now owns 813,647 shares of the biopharmaceutical company’s stock worth $46,516,000 after purchasing an additional 169,331 shares during the last quarter. OppenheimerFunds Inc. raised its position in shares of Agios Pharmaceuticals by 679.7% during the 4th quarter. OppenheimerFunds Inc. now owns 142,283 shares of the biopharmaceutical company’s stock worth $8,134,000 after purchasing an additional 124,035 shares during the last quarter. Finally, Lord Abbett & CO. LLC raised its position in shares of Agios Pharmaceuticals by 81.5% during the 2nd quarter. Lord Abbett & CO. LLC now owns 266,910 shares of the biopharmaceutical company’s stock worth $13,733,000 after purchasing an additional 119,836 shares during the last quarter. Hedge funds and other institutional investors own 84.04% of the company’s stock.

Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded up $3.12 on Tuesday, hitting $81.81. 772,200 shares of the stock were exchanged, compared to its average volume of 780,764. The stock has a market capitalization of $4,690.00, a price-to-earnings ratio of -12.14 and a beta of 2.12. Agios Pharmaceuticals has a 12-month low of $45.11 and a 12-month high of $83.92.

ILLEGAL ACTIVITY NOTICE: This report was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://stocknewstimes.com/2018/02/23/analysts-expect-agios-pharmaceuticals-inc-agio-will-post-earnings-of-1-60-per-share.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply